NewAmsterdam Pharma Co N.V. (NAMS)
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $22.5M
- Net income
- -$203.8M
- Total assets
- $769.3M
- Market cap
- $3.7B
- Operating margin
- -1002.9%
- Net margin
- -905.7%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $22.5M
- Operating expenses
- $248.2M
- Operating income
- -$225.7M
- Net income
- -$203.8M
- EPS (basic)
- $-1.72
- EPS (diluted)
- $-1.72
Balance sheet
- Total assets
- $769.3M
- Current assets
- $675.7M
- Total liabilities
- $85.9M
- Current liabilities
- $85.8M
- Shareholders’ equity
- $683.4M
Cash flow
- Operating cash flow
- -$147.8M
- Investing cash flow
- -$174.9M
- Financing cash flow
- $29.5M
- Net cash flow
- -$293.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.7B
- EPS (diluted)
- $-1.72
- Shares outstanding
- 124.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 23, 2022
NewAmsterdam Pharma Co N.V. (NAMS) Stock Price
- Reported a net loss of $203.8M in FY2025.
- Revenue grew 60% from FY2023 to FY2025.
- Trading 28% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NewAmsterdam Pharma Co N.V..
Write a review
News about NewAmsterdam Pharma Co N.V.
News & sentiment via Polygon.io
NewAmsterdam Pharma Co N.V.: frequently asked questions
Is NewAmsterdam Pharma Co N.V. an American company?
NewAmsterdam Pharma Co N.V. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is NewAmsterdam Pharma Co N.V. publicly traded?
Yes — NewAmsterdam Pharma Co N.V. is a publicly traded company. Its stock trades under the ticker symbol NAMS on the NASDAQ.
What does NewAmsterdam Pharma Co N.V. do?
NewAmsterdam Pharma Co N.V. is an American Pharmaceuticals company in the Health & Beauty sector.
